2024-03-29T10:17:43Z
http://repoint.unil.ch/oaiprovider/
oai:serval.unil.ch:BIB_C68C18567E23
2024-03-23T02:57:51Z
serval:BIB_C68C18567E23
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
10.1016/S1470-2045(18)30578-3
000451633800057
30442501
Ladenstein
R.
author
Pötschger
U.
author
Valteau-Couanet
D.
author
Luksch
R.
author
Castel
V.
author
Yaniv
I.
author
Laureys
G.
author
Brock
P.
author
Michon
J.M.
author
Owens
C.
author
Trahair
T.
author
Chan
GCF
author
Ruud
E.
author
Schroeder
H.
author
Beck Popovic
M.
author
Schreier
G.
author
Loibner
H.
author
Ambros
P.
author
Holmes
K.
author
Castellani
M.R.
author
Gaze
M.N.
author
Garaventa
A.
author
Pearson
ADJ
author
Lode
H.N.
author
article
2018-12
The Lancet. Oncology
1474-5488
1470-2045
journal
19
12
1617-1629
Adolescent
Age Factors
Antibodies, Monoclonal/administration & dosage
Antibodies, Monoclonal/adverse effects
Antineoplastic Combined Chemotherapy Protocols/adverse effects
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Child
Child, Preschool
Female
Humans
Infant
Interleukin-2/administration & dosage
Interleukin-2/adverse effects
Isotretinoin/administration & dosage
Male
Neuroblastoma/drug therapy
Neuroblastoma/immunology
Neuroblastoma/mortality
Neuroblastoma/pathology
Progression-Free Survival
Risk Factors
Time Factors
Young Adult
eng
60_published
peer-reviewed
Publication types: Clinical Trial, Phase III ; Comparative Study ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
Publication Status: ppublish